Purpose: To evaluate clinical outcomes of a combined therapy of laser photocoagulation and intravitreal bevacizumab for vitreous hemorrhage in Eales’ disease.

Methods: In the present retrospective study, medical records of patients who were treated with laser photocoagulation for vitreous hemorrhage due to Eales’ disease. The eyes were divided into 2 groups, the combined therapy group of laser photocoagulation and intravitreal bevacizumab, and the monotherapy group of laser photocoagulation. Best corrected visual acuity, vitreous hemorrhage grade were investigated at 1, 2, 6, and 9 months. Change of nonperfusion area and neovascularizaition area in fluorescein angiography were compared.

Results: Among 14 eyes, 7 eyes underwent intravitreal bevacizumab injection and 7 eyes did not. Visual acuity improved significantly at 1 and 3 months in the combined therapy group, but not in the monotherapy group. Vitreous hemorrhage decreased significantly at 1 and 3 months in the combined group, and 1 month in the monotherapy group. There was significant difference in visual acuity at 3 months and in vitreous hemorrhage at 1 and 3 months between the groups. Neovascularizaiton area was significantly regressed only in combined therapy group (p=0.027).

Conclusions: Combined laser photocoagulation with intravitreal bevacizumab injection decreased vitreous hemorrhage and neovascularization in Eales’ disease at 1 and 3 months after treatment. But these effect have not maintained thereafter.